Trials / Active Not Recruiting
Active Not RecruitingNCT06428500
QTX3046 in Patients With KRAS G12D Mutations
A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of QTX3046 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Quanta Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QTX3046 | QTX3046 will be administered at protocol defined dose. |
| COMBINATION_PRODUCT | Cetuximab | Cetuximab will be administered at protocol defined dose. |
Timeline
- Start date
- 2024-05-30
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2024-05-24
- Last updated
- 2025-07-25
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06428500. Inclusion in this directory is not an endorsement.